Mehrdad Kargari1, Samira Tavassoli2, Amir Avan3, Mahmoud Ebrahimi4, Mahmoud Reza Azarpazhooh4, Rasool Asoodeh5, Mohsen Nematy6, Seyed Mahdi Hassanian7, Farzad Rahmani7, Elham Mohammadzade6, Habibollah Esmaeili8, Mohsen Moohebati4, Gordon A Ferns9, Majid Ghayour-Mobarhan10, Seyed Mohammad Reza Parizadeh11. 1. Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran; Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Biochemistry, Payam Noor University of Mashhad, Mashhad, Iran. 3. Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Department of biostatistics and Epidemiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 8. Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Biochemistry, Payam Noor University of Mashhad, Mashhad, Iran. 9. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK. 10. Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: ghayourm@mums.ac.ir. 11. Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: Parizadehmr@mums.ac.ir.
Abstract
BACKGROUND: Heat shock protein 27 (HSP27) is an intracellular molecular chaperone that is expressed at high levels following the exposure of cells to environmental stressors such as heat, toxins, and free radicals. High levels of HSP antigens and antibody titers have been reported in several conditions including cardiovascular disease and cancers. We measured serum anti-HSP27 antibody levels in 993 subjects and assessed the associations between serum anti-HSP27 antibody levels and demographic characteristics including coronary risk factors. METHODS: A total of 993 subjects were recruited as part of the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study. Demographic, clinical, and biochemical parameters and serum anti-HSP27 antibody titers were determined in all the subjects. RESULTS: Serum anti-HSP27 antibody levels increased with increasing age in men. No significant differences in levels were detected between men and women. Serum anti-HSP27 antibody levels were significantly higher in obese subjects than in nonobese subjects (P=0.046); however, no significant influence of smoking status was observed. Moreover, serum anti-HSP27 antibody titers were positively associated with age, body mass index, waist/hip ratio, the presence of diabetes mellitus, nonsmoking habit, serum triglycerides, cholesterol, and high-sensitivity c-reactive protein. CONCLUSION: We have found that serum anti-HSP27 antibody titers are related to several cardiovascular risk factors, necessitating further studies on the value of this emerging marker for risk stratification.
BACKGROUND:Heat shock protein 27 (HSP27) is an intracellular molecular chaperone that is expressed at high levels following the exposure of cells to environmental stressors such as heat, toxins, and free radicals. High levels of HSP antigens and antibody titers have been reported in several conditions including cardiovascular disease and cancers. We measured serum anti-HSP27 antibody levels in 993 subjects and assessed the associations between serum anti-HSP27 antibody levels and demographic characteristics including coronary risk factors. METHODS: A total of 993 subjects were recruited as part of the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study. Demographic, clinical, and biochemical parameters and serum anti-HSP27 antibody titers were determined in all the subjects. RESULTS: Serum anti-HSP27 antibody levels increased with increasing age in men. No significant differences in levels were detected between men and women. Serum anti-HSP27 antibody levels were significantly higher in obese subjects than in nonobese subjects (P=0.046); however, no significant influence of smoking status was observed. Moreover, serum anti-HSP27 antibody titers were positively associated with age, body mass index, waist/hip ratio, the presence of diabetes mellitus, nonsmoking habit, serum triglycerides, cholesterol, and high-sensitivity c-reactive protein. CONCLUSION: We have found that serum anti-HSP27 antibody titers are related to several cardiovascular risk factors, necessitating further studies on the value of this emerging marker for risk stratification.